Literature DB >> 10972628

Diabetes guidelines: a summary and comparison of the recommendations of the American Diabetes Association, Veterans Health Administration, and American Association of Clinical Endocrinologists.

M J Clark1, J J Sterrett, D S Carson.   

Abstract

OBJECTIVE: This paper summarizes and compares 3 major organizations' guidelines for the management of diabetes mellitus.
BACKGROUND: Diabetes mellitus is a chronic disease that affects >16 million Americans. A decrease in adverse events has been demonstrated when hyperglycemia and comorbid conditions such as hypertension and dyslipidemia are controlled in patients with diabetes. Although each patient with diabetes is unique and medical care should be tailored to his or her individual needs, clinical evidence and expert opinion have established a baseline level of care for all patients with diabetes. Guidelines have been created to guide practitioners in selecting appropriate care, but their length and complexity may serve as barriers to their use.
METHODS: The diabetes management guidelines of the American Diabetes Association (ADA), Veterans Health Administration (VA), and American Association of Clinical Endocrinologists (AACE) are summarized and compared in both text and tabular form.
CONCLUSION: Although the guidelines published by the ADA, VA, and AACE vary slightly, all of them can be used to ensure that patients with diabetes receive appropriate care.

Entities:  

Mesh:

Year:  2000        PMID: 10972628     DOI: 10.1016/S0149-2918(00)80063-6

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  11 in total

1.  Simultaneous control of intermediate diabetes outcomes among Veterans Affairs primary care patients.

Authors:  George L Jackson; David Edelman; Morris Weinberger
Journal:  J Gen Intern Med       Date:  2006-10       Impact factor: 5.128

Review 2.  Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.

Authors:  Julia Kirchheiner; Ivar Roots; Mark Goldammer; Bernd Rosenkranz; Jürgen Brockmöller
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 3.  Adiposity and Alzheimer's disease.

Authors:  Jose A Luchsinger; Richard Mayeux
Journal:  Curr Alzheimer Res       Date:  2007-04       Impact factor: 3.498

4.  Activation of RAGE induces elevated O2- generation by mononuclear phagocytes in diabetes.

Authors:  Yong Ding; Alpdogan Kantarci; Hatice Hasturk; Philip C Trackman; Alan Malabanan; Thomas E Van Dyke
Journal:  J Leukoc Biol       Date:  2006-11-09       Impact factor: 4.962

5.  Phosphorylation of pleckstrin increases proinflammatory cytokine secretion by mononuclear phagocytes in diabetes mellitus.

Authors:  Yong Ding; Alpdogan Kantarci; John A Badwey; Hatice Hasturk; Alan Malabanan; Thomas E Van Dyke
Journal:  J Immunol       Date:  2007-07-01       Impact factor: 5.422

Review 6.  Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective.

Authors:  José Alejandro Luchsinger
Journal:  Eur J Pharmacol       Date:  2008-03-04       Impact factor: 4.432

Review 7.  Adiposity, type 2 diabetes, and Alzheimer's disease.

Authors:  José A Luchsinger; Deborah R Gustafson
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

Review 8.  Pathogenesis and management issues for non-alcoholic fatty liver disease.

Authors:  Marko Duvnjak; Ivan Lerotić; Neven Barsić; Vedran Tomasić; Lucija Virović Jukić; Vedran Velagić
Journal:  World J Gastroenterol       Date:  2007-09-14       Impact factor: 5.742

9.  Adapting clinical guidelines in low-resources countries: a study on the guideline on the management and prevention of type 2 diabetes mellitus in Indonesia.

Authors:  Indah S Widyahening; Grace Wangge; Yolanda van der Graaf; Geert J M G van der Heijden
Journal:  J Eval Clin Pract       Date:  2016-09-04       Impact factor: 2.431

Review 10.  Redefining diabetes mellitus treatments according to different mechanisms beyond hypoglycaemic effect.

Authors:  Savina Nodari; Francesco Fioretti; Francesco Barilla
Journal:  Heart Fail Rev       Date:  2022-02-08       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.